Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis. (SALTEA GABAbr)

Civil Hospices of Lyon

Status: Completed

Conditions: Autoimmune Encephalitis

Treatments: Other: Long-term outcome

Study type: Observational

Funder types: Other

Identifiers

NCT05741619

897

Details and patient eligibility

About

First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC).

While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative.

In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.

Enrollment: 70 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• encephalitis tested positive to GABAbr-antibodies after the examination of CSF samples tested for autoimmune encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center from January 2011 to January 2022.

Exclusion criteria

• tested positive to another onconeural antibody.

Trial design

70 participants in 1 patient group

Anti-GABABr encephalitis

Description:

This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.

Treatment:

Other: Long-term outcome